Metabolically Unhealthy Non-Obesity: The Hidden Epidemic in Cardiometabolic Disease

Dr Neeraj Manikath , claude.ai

Abstract

Metabolically unhealthy normal weight (MUNW) or "non-obese metabolic obesity" represents a paradoxical phenotype affecting 10-30% of normal-weight individuals who exhibit obesity-related metabolic dysfunction. This population faces cardiovascular disease risk comparable to or exceeding that of obese individuals, challenging traditional BMI-centric approaches to cardiometabolic risk assessment. This review examines the pathophysiology, diagnostic criteria, clinical implications, and management strategies for this under-recognized condition, with practical pearls for internists.

Introduction

The paradigm that obesity, defined by body mass index (BMI) ≥30 kg/m², invariably correlates with metabolic dysfunction has been increasingly challenged. Approximately 20-35% of obese individuals are "metabolically healthy," while conversely, 10-30% of normal-weight individuals (BMI 18.5-24.9 kg/m²) display metabolic abnormalities traditionally associated with obesity.[1,2] This latter group—termed metabolically unhealthy normal weight (MUNW), metabolically obese normal weight (MONW), or having normal weight obesity (NWO)—represents a critical blind spot in contemporary medicine.

Pearl #1: A normal BMI does not exclude cardiometabolic risk. Always assess metabolic health independent of body weight.

Defining the Phenotype

While no universally accepted definition exists, MUNW is generally characterized by normal BMI (18.5-24.9 kg/m²) in conjunction with ≥2 of the following metabolic abnormalities:[3,4]

• Insulin resistance (HOMA-IR >2.5)
• Elevated triglycerides (≥150 mg/dL)
• Low HDL-cholesterol (<40 mg/dL men, <50 mg/dL women)
• Elevated blood pressure (≥130/85 mmHg)
• Impaired fasting glucose (≥100 mg/dL) or dysglycemia
• Elevated high-sensitivity C-reactive protein (>3 mg/L)
• Increased waist circumference despite normal BMI (>80 cm women, >90 cm men for Asians)

Importantly, some investigators define MUNW using body composition criteria: normal BMI but elevated body fat percentage (>30% in women, >20% in men) combined with metabolic dysfunction.[5]

Oyster #1: The term "metabolic syndrome" requires waist circumference criteria that many MUNW individuals don't meet, potentially missing this high-risk population. Consider using individual metabolic parameters rather than rigid syndrome criteria.

Epidemiology and Clinical Significance

Global prevalence estimates of MUNW vary widely (7-30%) depending on population characteristics and diagnostic criteria employed.[2,6] A meta-analysis by Kramer et al. found that MUNW individuals had 3-fold higher cardiovascular disease risk and 2.6-fold higher all-cause mortality compared to metabolically healthy normal-weight individuals.[7]

The Framingham Heart Study demonstrated that normal-weight individuals with metabolic syndrome had higher cardiovascular mortality than metabolically healthy obese individuals.[8] Data from the Korean NHANES showed MUNW individuals had significantly higher prevalence of subclinical atherosclerosis and coronary artery calcium scores compared to metabolically healthy counterparts.[9]

Pearl #2: Risk calculators like the Framingham Risk Score may underestimate cardiovascular risk in MUNW patients because they don't adequately weight metabolic parameters in normal-weight individuals.

Pathophysiology: Unraveling the Paradox

Visceral Adiposity and Ectopic Fat Deposition

The fundamental mechanism underlying MUNW is unfavorable fat distribution despite normal total body fat. These individuals demonstrate:[10,11]

1. Increased visceral adipose tissue (VAT): CT and MRI studies reveal elevated VAT-to-subcutaneous adipose tissue (SAT) ratios
2. Ectopic fat accumulation: Hepatic steatosis, myocardial lipid deposition, and intramuscular fat infiltration
3. Dysfunctional adipose tissue: Impaired adipocyte expandability leads to lipotoxicity in peripheral organs

Hack #1: Consider ordering abdominal CT or ultrasound in normal-weight patients with metabolic abnormalities. Visceral fat area >100 cm² on CT at L4-L5 level indicates pathological visceral adiposity even with normal BMI.

Sarcopenic Obesity

Many MUNW individuals have concurrent sarcopenia—reduced skeletal muscle mass and quality—which exacerbates metabolic dysfunction through:[12]

• Reduced glucose disposal capacity (muscle is the primary insulin-sensitive tissue)
• Decreased basal metabolic rate
• Increased inflammatory cytokine production from adipose tissue
• Impaired mitochondrial function

Genetic and Ethnic Considerations

Asian populations demonstrate higher susceptibility to MUNW at any given BMI, related to genetic predisposition for visceral fat accumulation and lower muscle mass.[13] Specific polymorphisms in genes regulating adipogenesis (PPARG, FTO, MC4R) and insulin signaling (IRS1, TCF7L2) have been implicated.[14]

Pearl #3: Apply ethnic-specific BMI and waist circumference cut-offs. For Asian patients, consider BMI ≥23 kg/m² as "overweight" and waist circumference >90 cm (men) or >80 cm (women) as elevated.

Inflammatory and Hormonal Dysregulation

MUNW is characterized by:[15,16]

• Elevated inflammatory markers (IL-6, TNF-α, hsCRP)
• Adipokine imbalance (reduced adiponectin, elevated leptin)
• Hypothalamic-pituitary-adrenal axis dysregulation
• Sex hormone alterations (hyperandrogenism in women, hypogonadism in men)

Clinical Presentation and Diagnosis

The Diagnostic Approach

Hack #2: Create a "metabolic panel plus" for normal-weight patients with risk factors:

• Standard lipid panel with particle size analysis
• Fasting glucose and insulin (calculate HOMA-IR)
• HbA1c
• hsCRP
• Liver function tests and hepatic steatosis index
• Uric acid
• 25-hydroxyvitamin D
• Consider: adiponectin, leptin levels

Who to Screen?

Target normal-weight individuals with:[17]

• Family history of type 2 diabetes or premature CVD
• Personal history of gestational diabetes or PCOS
• Sedentary lifestyle (<150 min/week moderate activity)
• Poor dietary quality (high processed foods, low fiber)
• South Asian, East Asian, or Hispanic ethnicity
• Sleep disorders or chronic stress
• Acanthosis nigricans or skin tags
• Fatty liver on imaging

Oyster #2: Don't dismiss hypertension or prediabetes in normal-weight patients as "white coat" or "borderline." These may signal MUNW requiring aggressive intervention.

Risk Assessment and Prognosis

MUNW confers substantial long-term risks:[18,19]

• Type 2 diabetes: 3-5 fold increased incidence over 10 years
• Cardiovascular disease: 2-3 fold higher risk of myocardial infarction and stroke
• Non-alcoholic fatty liver disease: 60-70% prevalence, with higher progression to NASH
• Chronic kidney disease: Accelerated GFR decline
• Dementia: Emerging evidence links midlife metabolic dysfunction with later cognitive decline

Pearl #4: Consider calculating coronary artery calcium scores in MUNW patients >40 years with additional risk factors. A score >0 should prompt statin therapy regardless of LDL levels.

Management Strategies

Lifestyle Modifications: The Cornerstone

Exercise Prescription:

• Resistance training: Essential for addressing sarcopenia; 2-3 sessions weekly of major muscle groups
• High-intensity interval training (HIIT): Superior for reducing visceral fat and improving insulin sensitivity
• Combined aerobic + resistance: 150-300 min/week moderate intensity plus twice-weekly strength training[20]

Hack #3: Prescribe exercise like medication: "Resistance training: 3 sets of 10-12 repetitions, 8 major muscle groups, twice weekly. Follow-up: 3 months." This clarity improves adherence.

Nutritional Intervention:

• Mediterranean diet pattern (demonstrated to reduce VAT specifically)[21]
• Adequate protein intake (1.2-1.6 g/kg/day) to preserve muscle mass
• Limit ultra-processed foods and added sugars
• Consider time-restricted eating (16:8 protocol) for improving insulin sensitivity[22]

Pearl #5: Body recomposition, not weight loss, is the goal. Monitor waist circumference, muscle mass, and metabolic parameters—not scale weight.

Pharmacological Considerations

While lifestyle remains primary, selected patients may benefit from:

Metformin:

• Consider in MUNW with prediabetes (HbA1c 5.7-6.4%) and additional risk factors
• Particularly effective in those with PCOS or strong diabetes family history
• Dose: 500-2000 mg daily[23]

GLP-1 Receptor Agonists:

• Emerging role beyond diabetes treatment
• Reduce visceral fat, improve insulin sensitivity, and provide cardiovascular benefits
• Consider in MUNW with prediabetes not responding to lifestyle measures[24]

Statins:

• Indicated by standard cardiovascular risk algorithms
• Don't withhold based on normal weight—treat the metabolic phenotype

Oyster #3: Insurance often denies GLP-1 agonists for normal-weight individuals despite metabolic indications. Document visceral adiposity on imaging and metabolic syndrome criteria to support prior authorization.

Monitoring and Follow-up

Establish regular monitoring:[25]

• Quarterly: Weight, waist circumference, blood pressure
• Biannually: Fasting glucose, HbA1c, lipid panel, liver enzymes
• Annually: hsCRP, microalbuminuria, comprehensive metabolic assessment
• Body composition analysis: DEXA or bioelectrical impedance every 6-12 months

Hack #4: Use waist-to-height ratio (WHtR) as a simple screening tool. WHtR >0.5 indicates increased cardiometabolic risk regardless of BMI. Easier than remembering ethnic-specific waist circumference cut-offs.

Special Populations

Women with PCOS

Exhibit high rates of MUNW (30-40%) due to hyperandrogenism and insulin resistance. Require aggressive metabolic screening and early intervention.[26]

Post-Menopausal Women

Hormonal changes shift fat distribution from subcutaneous to visceral depots, increasing MUNW prevalence without weight gain.

Young Adults with Poor Fitness

"Skinny fat" phenotype increasingly common in sedentary young adults with high processed food consumption. Early identification prevents future cardiometabolic disease.

Future Directions and Research Needs

Emerging areas include:

• Genetic risk scores incorporating MUNW-specific polymorphisms
• Advanced imaging biomarkers (MRI proton density fat fraction)
• Metabolomic signatures for early MUNW detection
• Novel therapeutics targeting visceral adiposity specifically
• Long-term outcomes data comparing MUNW to traditional obesity phenotypes

Conclusion

Metabolically unhealthy non-obesity represents a critical, under-recognized cardiovascular risk state that challenges BMI-centric approaches to health assessment. Internists must maintain high clinical suspicion for metabolic dysfunction in normal-weight individuals, particularly those with family history, sedentary lifestyle, or ethnic predisposition. Management focuses on body recomposition through resistance training, dietary modification, and selective pharmacotherapy when indicated. The mantra "thin does not equal healthy" must permeate clinical practice, with risk assessment individualized to metabolic phenotype rather than body weight alone.

Final Pearl: Educate patients that health is determined by metabolic function and body composition, not scale weight. This reframes goals from "losing weight" to "gaining metabolic health"—a more achievable and sustainable paradigm for normal-weight individuals with metabolic dysfunction.

---

References

1. Stefan N, et al. Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol. 2013;1(2):152-162.

2. Ruderman N, et al. The metabolically obese, normal-weight individual revisited. Diabetes. 1998;47(5):699-713.

3. Karelis AD, et al. Metabolic and body composition factors in subgroups of obesity: what do we know? J Clin Endocrinol Metab. 2004;89(6):2569-2575.

4. Wildman RP, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering. Arch Intern Med. 2008;168(15):1617-1624.

5. De Lorenzo A, et al. Normal-weight obese syndrome: early inflammation? Am J Clin Nutr. 2007;85(1):40-45.

6. Romero-Corral A, et al. Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality. Eur Heart J. 2010;31(6):737-746.

7. Kramer CK, et al. Are metabolically healthy overweight and obesity benign conditions? Ann Intern Med. 2013;159(11):758-769.

8. Meigs JB, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab. 2006;91(8):2906-2912.

9. Kim MK, et al. Metabolically unhealthy normal weight is associated with increased risk of cardiovascular disease: a Korean nationwide cohort study. Diabetes Care. 2014;37(11):3069-3075.

10. Neeland IJ, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease. Lancet. 2019;393(10170):462-473.

11. Thomas EL, et al. The missing risk: MRI and MRS phenotyping of abdominal adiposity and ectopic fat. Obesity. 2012;20(1):76-87.

12. Poggiogalle E, et al. Sarcopenic obesity and metabolic syndrome in adult Caucasian subjects. J Nutr Health Aging. 2016;20(9):958-963.

13. Misra A, Vikram NK. Clinical and pathophysiological consequences of abdominal adiposity and abdominal adipose tissue depots. Nutrition. 2003;19(5):457-466.

14. Loos RJF, Yeo GSH. The genetics of obesity: from discovery to biology. Nat Rev Genet. 2022;23(2):120-133.

15. Conus F, et al. Characteristics of metabolically obese normal-weight (MONW) subjects. Appl Physiol Nutr Metab. 2007;32(1):4-12.

16. Katsuki A, et al. Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes Care. 2001;24(2):362-365.

17. Aung K, et al. Risk profile and complications of diabetes in patients with normal body mass index. World J Diabetes. 2014;5(6):917-923.

18. De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. J Obes. 2013;2013:291546.

19. Arnlöv J, et al. Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation. 2010;121(2):230-236.

20. Willis LH, et al. Effects of aerobic and/or resistance training on body mass and fat mass in overweight or obese adults. J Appl Physiol. 2012;113(12):1831-1837.

21. Estruch R, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368(14):1279-1290.

22. Sutton EF, et al. Early time-restricted feeding improves insulin sensitivity, blood pressure, and oxidative stress. Cell Metab. 2018;27(6):1212-1221.

23. Diabetes Prevention Program Research Group. Long-term effects of metformin on diabetes prevention. Diabetes Care. 2015;38(6):1004-1011.

24. Lean MEJ, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391(10120):541-551.

25. Garvey WT, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1-203.

26. Lim SS, et al. Metabolic syndrome in polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. Obes Rev. 2019;20(2):339-352.